About this trial
Nephrotoxicity is a great concern in patients receiving intravenous colistin and there is a disparity in the reported rates between previous studies. Several preclinical researches studied the effect of the antioxidants (e.g. L.carnitine, vitamin C, vitamin E, N-acetyl cysteine, and alpha lipoic acid) in reducing the risk of colistin-induced nephrotoxicity but there is a lack of clinical studies on human. Due to the paucity of studies that early predict colistin-induced nephrotoxicity using early acute kidney injury "AKI" biomarkers e.g. kidney injury molecule 1"KIM1" and the lack of human studies that evaluate the role of alpha lipoic acid in ameliorating colistin-induced nephrotoxicity, so this study will be conducted.
Eligibility criteria
Qualifiers
Adult patients who receive intravenous colistin and had positive cultures of multidrug resistant gram negative bacteria.
Patients who receive colistin for at least 3 days during their treatment.
Disqualifiers
Patients who receive inhaled colistin.
Patients who had AKI at baseline
chronic kidney disease patients on regular hemodialysis.
Renal transplant patients
Trial design
Treatments tested in this trial
- alpha lipoic acid drug (thioctic acid acid)